Drug Trial News

RSS

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

SARAH, a large French study of patients with advanced, inoperable primary liver cancer (hepatocellular carcinoma, or HCC) has completed patient enrolment, exceeding its 400-patient target, according to its principal investigator, Professor Valérie Vilgrain MD, PhD, Department of Radiology, Beaujon Hospital, Assistance Publique - Hôpitaux de Paris (AP-HP) and Université Paris Diderot, Sorbonne Paris Cité, France.

4 Mar 2015

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Alizé Pharma, a company specialized in the development of drugs for the treatment of metabolic disorders and rare diseases, today announces the launch of a Phase II clinical trial of AZP-531, its unacylated ghrelin analog, in patients with Prader-Willi syndrome.

3 Mar 2015

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Patients Receiving Kyprolis Lived Twice as Long without Disease Progression

2 Mar 2015

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Transition Therapeutics Inc. announced that its wholly owned subsidiary, Transition Therapeutics Ireland Limited completed enrolment of the Phase 2 clinical study evaluating neuropsychiatric drug candidate ELND005 as a treatment for agitation and aggression in patients with mild, moderate and severe Alzheimer's disease ("AD").

2 Mar 2015

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

Pharmacyclics, Inc. today announced that longer-term toxicology studies for its newly developed Bruton's tyrosine kinase (BTK) inhibitor for rheumatoid arthritis, or RA, have been completed.

28 Feb 2015

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study published online in JAMA Oncology.

28 Feb 2015

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

Bionomics Limited is to present important additional data from the DisrupTOR-1 trial of BNC105 in patients with metastatic renal cancer at the ASCO Genitourinary Cancers Symposium in Orlando, Florida. The data will be presented by Dr. Sumanta Pal of the City of Hope Comprehensive Cancer Center in California in his poster presentation.

28 Feb 2015

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases today launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study, which will be conducted in Liberia and the United States, is a randomized controlled trial enrolling adults and children with known Ebola virus infection.

27 Feb 2015

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

Although levodopa remains the "gold standard" to effectively control motor deficits in the treatment of early stage Parkinson's disease (PD), it loses effectiveness as the disease progresses. After four to six years of treatment with oral medications for Parkinson's disease, about 40% of patients experience lack of muscle control (dyskinesias), end-of-dose wearing off, and fluctuations in "On/Off" states.

27 Feb 2015

EORTC researchers review potential treatment options for patients with locally advanced breast cancer

Treating patients with locally advanced inoperable breast cancer is an extremely difficult task. The overwhelming majority of patients treated for this disease suffer relapse and, despite the best multimodal treatment, do not survive. There is a medical need to examine current and potential treatments, and EORTC researchers have recently published an article in Nature Reviews Clinical Oncology concerning this topic.

27 Feb 2015

New cancer drug enters phase I clinical trials in humans

A new drug that prompts cancer cells to self-destruct while sparing healthy cells is now entering phase I clinical trials in humans. The drug, called PAC-1, first showed promise in the treatment of pet dogs with spontaneously occurring cancers, and is still in clinical trials in dogs with osteosarcoma.

27 Feb 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

EKF Diagnostics subsidiary, Selah Genomics, has announced a major, four-way collaboration with Greenville Health System, DecisionQ Corporation, and BD.

From EKF Diagnostics 26 Feb 2015

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Inflectra is licensed for the treatment of inflammatory conditions including rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis, adult and paediatric Crohn’s disease, adult and paediatric ulcerative colitis and plaque psoriasis.

26 Feb 2015

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).

25 Feb 2015

Reslizumab drug appears to reduce risk of severe asthma attacks

An investigational drug appears to cut the risk of severe asthma attacks in half for patients who have difficulty controlling the disorder with standard medications, according to results from two multicenter clinical trials.

25 Feb 2015

Actavis files ANDA to market Budesonide Extended-release Tablets

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Budesonide Extended-release Tablets, 9 mg.

25 Feb 2015

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).

24 Feb 2015

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Two widely used targeted therapy drugs— approved by the FDA for use in metastatic kidney cancer —are no more effective than a placebo in preventing return of the disease to increase life spans of patients suffering from advanced kidney cancer after surgery, according to new results to be presented by a researcher at the University of Pennsylvania's Abramson Cancer Center during the 2015 Genitourinary Cancers Symposium.

24 Feb 2015

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Boehringer Ingelheim today presented data on investigational tiotropium delivered via Respimat inhaler from five Phase III trials from the UniTinA-asthma program at the 2015 American Academy of Allergy, Asthma & Immunology Annual Meeting in Houston, Texas.

24 Feb 2015

Drug Trial News

SARAH study completes patient enrolment to evaluate treatment for primary liver cancer

Alizé Pharma announces launch of AZP-531 Phase II trial in patients with Prader-Willi syndrome

Kyprolis demonstrates superiority over velcade in patients with relapsed multiple myeloma in head-to-head endeavor trial

Transition completes enrolment of patients in ELND005 Phase 2 study for treatment of AD patients

Pharmacyclics completes toxicology studies of BTK inhibitor in RA

CLL patients discontinue ibrutinib drug due to disease progression during clinical trials

Bionomics to present data from DisrupTOR-1 trial at ASCO Genitourinary Cancers Symposium

NIAID partners with Liberian government to test ZMapp drug for Ebola virus disease

Study: Levodopa-carbidopa intestinal gel improves quality of life in advanced PD patients

EORTC researchers review potential treatment options for patients with locally advanced breast cancer

New cancer drug enters phase I clinical trials in humans

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

New four-way collaboration aims to improve clinical decision-making in the treatment of colon cancer

Hospira launches first biosimilar monoclonal antibody (mAb) InflectraTM (infliximab) in the UK

Sorafenib, sunitinib provide no benefit to patients with locally advanced kidney cancer

Reslizumab drug appears to reduce risk of severe asthma attacks

Actavis files ANDA to market Budesonide Extended-release Tablets

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Two widely used targeted therapy drugs not effective in preventing return of kidney cancer

Boehringer Ingelheim presents Phase III data for tiotropium at 2015 AAAAI Annual Meeting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News